Cargando…

A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies

Detalles Bibliográficos
Autor principal:	Kim, Hun Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705042/ https://www.ncbi.nlm.nih.gov/pubmed/26770944 http://dx.doi.org/10.5045/br.2015.50.4.189

Ejemplares similares

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Genomic Stratification of Hematological Malignancies
por: Robbe, Pauline, et al.
Publicado: (2023)

Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies
por: Raza, Yasharah, et al.
Publicado: (2022)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2021)

Clusterin: a multifaceted protein in the brain
por: Moon, Hee-Jung, et al.
Publicado: (2020)

Multifaceted roles of pericytes-interorgan interactions
por: Zheng, Zhitong, et al.
Publicado: (2020)

Monitoring NK cell activity in patients with hematological malignancies
por: Viel, Sébastien, et al.
Publicado: (2013)

NK cell-based immunotherapy for treating cancer: will it be promising?
por: Cho, Duck, et al.
Publicado: (2011)

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
por: Morillo, Daniel, et al.
Publicado: (2023)

Matricellular proteins: multifaceted extracellular regulators in tumor dormancy
por: Wu, Tiantian, et al.
Publicado: (2014)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

Ivermectin as a multifaceted drug in COVID-19: Current insights
por: Khandelwal, Ankur, et al.
Publicado: (2021)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

‘Obesities’: Position statement on a complex disease entity with multifaceted drivers
por: Yárnoz‐Esquiroz, Patricia, et al.
Publicado: (2022)

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
por: Wolska-Washer, Anna, et al.
Publicado: (2022)

ASH Registry Offers Insights on COVID‐19 in Patients with Hematologic Malignancies
Publicado: (2020)

Decommissioning care: The need for rigorous multifaceted evaluations of decisions to withdraw health services
por: Sheikh, Aziz
Publicado: (2017)

DECLARE: A Comprehensive, Multifaceted Cognitive Forcing Strategy to Confront Complex Cases
por: Shimizu, Taro
Publicado: (2023)

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease
por: Thornton, Emma, et al.
Publicado: (2015)

Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies
por: Irrera, Natasha, et al.
Publicado: (2021)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies
por: Ramos-Mejia, Veronica, et al.
Publicado: (2022)

Mucositis and Infection in Hematology Patients
por: Blijlevens, Nicole M. A., et al.
Publicado: (2023)

Coronavirus disease-19 and its hematological manifestations
por: Kim, Hye-Ran, et al.
Publicado: (2020)

Nanomedicine approaches for treatment of hematologic and oncologic malignancies
por: Nteli, Polyxeni, et al.
Publicado: (2022)

Improving tuberculosis diagnosis: Better tests or better healthcare?
por: Datta, Sumona, et al.
Publicado: (2017)

DJ-1 as a deglycating enzyme: a unique function to explain a multifaceted protein?
por: De Lazzari, Federica, et al.
Publicado: (2017)

The multifaceted potential of the lipid transmitter oleoylethanolamide to treat alcohol-induced neuroinflammation and alcohol use disorders
por: Orio, Laura
Publicado: (2019)

Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
por: Müller-Nedebock, Amica C., et al.
Publicado: (2023)

Obesity paradox in cancer: Is bigger really better?
por: Ujvari, Beata, et al.
Publicado: (2019)

The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
por: Witalisz-Siepracka, Agnieszka, et al.
Publicado: (2022)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jqbm55g5t8f83buema96vuaarq